289 patents
Page 10 of 15
Utility
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
16 Feb 21
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate.
Jerry Lee Atwood
Filed: 2 Mar 20
Utility
Treatment of immune-related and inflammatory diseases
16 Feb 21
Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases.
Peter H. Schafer, Rajesh Chopra, Anita Gandhi
Filed: 8 Aug 13
Utility
Solid Forms of 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE, and Their Pharmaceutical Compositions and Uses
11 Feb 21
Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.
Paul F. Fernandez, Antonio C. Ferretti, Ying Li, Weihong Zhang
Filed: 18 Mar 20
Utility
Antiproliferative Compounds, and Their Pharmaceutical Compositions and Uses
11 Feb 21
Compounds of formula A-I and B-I, compositions comprising the compounds, methods of making the compounds and methods of their uses are disclosed.
Matthew D. Alexander, Matthew D. Correa, Joshua Hansen, Raj Kumar Raheja, John Sapienza
Filed: 6 Mar 20
Utility
Crystalline 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE Hemihydrate, Compositions and Methods of Use Thereof
28 Jan 21
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate.
Jerry Lee Atwood
Filed: 1 Oct 20
Utility
Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
26 Jan 21
Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
Filed: 10 Apr 20
Utility
Methods of Treating Hematological Disorders, Solid Tumors, or Infectious Diseases Using Natural Killer Cells
14 Jan 21
Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.
Lin KANG, Xiaokui ZHANG, Jeffrey HARRIS, Vladimir JANKOVIC
Filed: 18 Feb 20
Utility
Compositions and Methods for Inducing Conformational Changes In Cereblon and Other E3 Ubiquitin Ligases
6 Jan 21
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
Filed: 16 Apr 20
Utility
Compositions and Methods for Inducing Conformational Changes In Cereblon and Other E3 Ubiquitin Ligases
6 Jan 21
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
Filed: 20 Jul 20
Utility
Methods of Expanding T Cells
30 Dec 20
Provided herein are methods in the field of cell culture, specifically of culture and expansion of immune cells, e.g., T lymphocytes.
Stewart Abbot, Willard Foss, Thomas Daniel
Filed: 14 Apr 20
Utility
Combination Therapy for Treating Malignancies
30 Dec 20
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and a DNA demethylating agent.
Samuel V. Agresta, Krishnan Viswanadhan, Jorge Dimartino, Vivek Saroj Kumar Chopra, Kyle J. Macbeth, Robert Douglas Knight, Laurie Kenvin, Qiang Xu
Filed: 12 Apr 20
Utility
Bcma-binding Antibodies and Uses Thereof
23 Dec 20
Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.
Mahan Abbasian, Henry Chan, Kandasamy Hariharan, Jeonghoon Sun, Andrew Wurmser
Filed: 19 Feb 19
Utility
Anti-CD47 antibodies and uses thereof
21 Dec 20
Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47.
Aaron Sato, Ryan Stafford, Junhao Yang
Filed: 27 Dec 15
Utility
Substituted 1-OXO-ISOINDOLINE-5-CARBOXAMIDE Compounds, Compositions Thereof, and Methods of Treatment Therewith
2 Dec 20
Frans Baculi, Katherine Northcote, Matthew D. Correa, Joshua Hansen, Laurie A. Lebrun, Chin-Chun Lu, Gang Lu, Mark A. Nagy, Sophie Peng, Sophie Perrin-Ninkovic
Filed: 28 May 20
Utility
Methods of Synthesis of (1R,2R,5R)-5-AMINO-2-METHYLCYCLOHEXANOL Hydrochloride and Intermediates Useful Therein
25 Nov 20
Provided herein are methods and intermediates for making (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
Terrence Joseph CONNOLLY, Hon-Wah MAN
Filed: 12 Aug 20
Utility
3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE for the Treatment of Systemic Lupus Erythematosus
18 Nov 20
Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE).
Peter H. Schafer, Lei Wu, Ying Ye
Filed: 24 Feb 20
Utility
Salts and Solid Forms of (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE and Compositions Comprising and Methods of Using the Same
18 Nov 20
Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed.
Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
Filed: 24 Feb 20
Utility
Solid forms comprising 4-amino-2-(2,6- dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof
16 Nov 20
Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer.
G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer
Filed: 30 Jun 19
Utility
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
9 Nov 20
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate.
Jerry Lee Atwood
Filed: 30 Oct 19
Utility
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
9 Nov 20
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
Filed: 26 Dec 16